BullishWhales · Analysts · Analyst Profile
Analyst rating accuracy & track record
Eric Schmidt does not yet have enough resolved 12-month calls to carry a published score. Check back as their ratings mature.
Ratings & price targets
| Stock | Rating | Price target | Rated | 12-mo vs sector | PT hit |
|---|---|---|---|---|---|
 IMTXImmatics NV | Buy | — | Apr 2025 | +135.8% | — |
 BCAXBicara Therapeutics Inc. Common Stock | Buy | $13.01 | Mar 2025 | +49.3% | Hit |
 ADCTADC Therapeutics SA | Buy | — | Mar 2025 | +138.2% | — |
 PRTAProthena Corporation plc | Buy | — | Feb 2025 | −49.7% | — |
 AGIOAgios Pharm | Buy | — | Dec 2024 | −45.9% | — |
| BCAXBicara Therapeutics Inc. Common Stock | Buy | — | Oct 2024 | −7.3% | — |
| IMTXImmatics NV | Buy | — | Sep 2024 | −42.0% | — |
| IMTXImmatics NV | Buy | — | Sep 2024 | −37.7% | — |
| ADCTADC Therapeutics SA | Buy | — | May 2024 | −3.7% | — |
| IMTXImmatics NV | Buy | — | Nov 2023 | −20.7% | — |
Go to
Browse the full analyst leaderboardHow analyst accuracy is scored
Every score, Win %, PT Hit % and rank is an estimate Bullish Whales calculates from its own data and may not be 100% accurate or complete. Returns are measured in excess of each rated stock's own sector over the 12 months after each call. Past performance does not guarantee future results, and nothing here is a recommendation to buy or sell any security.